Laino, Andressa S.
Betts, B. C.
Veerapathran, A.
Dolgalev, I.
Sarnaik, A.
Quayle, S. N.
Jones, S. S.
Weber, J. S.
Woods, David M.
Funding for this research was provided by:
National Cancer Institute (1P50CA168536-01A1, R01 CA175732-01)
Article History
Received: 4 July 2018
Accepted: 21 January 2019
First Online: 6 February 2019
Ethics approval and consent to participate
: All protocols were approved by the Institutional Review Board at H. Lee Moffitt Cancer Center (IRB 106509, 107,273; Tampa, FL), and cells were obtained under a Materials Transfer Agreement. Samples were coded with an anonymized 5-digit number and their identity was unknown to those performing the experiments.
: Not applicable.
: Andressa S. Laino: Received one-year of grant funding from Acetylon Pharmaceuticals, in 2016.Brian C. Betts: The author declares no potential conflicts of interest.Anandharaman Veerapathran: The author declares no potential conflicts of interest.Igor Dolgalev: The author declares no potential conflicts of interest.Amod Sarnaik: Paid consultant for Iovance Biotherapeutics Inc. and B4CC Inc., and has received research funding support from Provectus, Iovance and Genentech.Steven N. Quayle: Former employee and stockholder of Acetylon Pharmaceuticals.Simon S. Jones: Former employee and stockholder of Acetylon Pharmaceuticals.Jeffrey S. Weber: Has stock or other ownership in Altor BioScience, Celldex, Biond and CytomX Therapeutics. Has honoraria in Bristol-Myers Squibb, Merck, Genentech, AbbVie, AstraZeneca, Daiichi Sankyo, GlaxoSmithKline, Eisai, Altor BioScience, Amgen, Roche, Ichor Medical Systems, Celldex, CytomX Therapeutics, Nektar, Novartis, Array, WindMIL, Takeda and Sellas. Has consulting or advisory role in Celldex, Ichor Medical Systems, Pieris Pharmaceuticals, Altor BioScience, Bristol-Myers Squibb, Merck, Genentech, Roche, Amgen, AstraZeneca, GlaxoSmithKline, Daiichi Sankyo, AbbVie, Eisai, CytomX Therapeutics, Nektar, Novartis, Array, WindMIL, Takeda and Sellas. Received research funding (to the Institution) from Bristol-Myers Squibb, Merck, GlaxoSmithKline, Genentech, Astellas Pharma, Incyte, Roche and Novartis. Received one-year of grant funding from Acetylon Pharmaceuticals. Received travel, accommodations, expenses from Bristol-Myers Squibb, GlaxoSmithKline, Daiichi Sankyo, Roche, Celldex, Amgen, Merck, AstraZeneca, Genentech, Novartis, Incyte, WindMIL and Takeda.David M. Woods: Received research funding from Mirati Therapeutics, in 2016 and 2017. Has stock in Bristol-Myers Squibb, Merck, GlaxoSmithKline, Seattle Genetics, Mirati Therapeutics, Iovance Biotherapeutics, Cue Biopharma, Fate Therapeutics, Atra Biotherapeutics, and Fortress Biotech.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.